Effect of Monotherapy with Methotrexate, Etanercept and their Combination on the Quality of Life in Children with Early and Late Juvenile Idiopathic Arthritis: A Prospective Study

Background. An important goal of treating patients with juvenile idiopathic arthritis (JIA) is to achieve the best quality of life associated with health. Objective. Our aim was to assess the impact of methotrexate plus etanercept therapy on the quality of life of patients with early and late JIA. Methods. The prospective study included patients with early and late JIA without systemic manifestations. The patients’ quality of life was assessed with the help of questionnaires for children and parents: the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale, the Pediatric Quality of Life Inventory (PedsQL) Rheumatology Module, and the Health Utilities Index Mark 3 (HUI3). The quality of life was assessed prior to the therapy and after one, six, and 12 months of treatment. Results. 150 children with JIA aged 5.1 (2.0; 17.7) years; 50 children aged 4.0 (2.3–11.4) years in the group of etanercept monotherapy, 50 children aged 5.0 (3.2–9.0) years in the group of methotrexate monotherapy, and 50 children aged 9.9 (6.4–13.0) years in the group of methotrexate plus etanercept combination therapy. All groups showed low scores on all questionnaires before treatment, compared to healthy children. In the course of therapy, there was a tendency for score increase to almost 1.0 according to the HUI3 questionnaire in all groups. After one year of etanercept therapy, the parameters of the quality of life of children with early JIA did not differ from healthy children; the score increased from 56 to 90 p = 0.942 according to the physical functioning scale and from 60 to 85 p = 0.889 according to the emotional functioning scale. In the 2nd group, there was a tendency for score increase, but a statistically significant difference was found across all scales of the questionnaire. After 12 months of etanercept plus methotrexate combination therapy in patients with late JIA, the questionnaire analysis showed that the responses of healthy children and children with JIA differed with probability p = 0.001 for the physical functioning scale, p = 0.001 for the social functioning scale, p = 0.001 for role functioning, and p = 0.001 for the total score. The score increase from 60 to 85 p = 0.789 was noted for emotional functioning scales. Conclusion. The use of questionnaires to assess the quality of life in children with severe chronic diseases can significantly improve the efficacy of treatment and ensure its control.

1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29(7):1520–1530.

2. Broughton T, Armon K. Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus. Pediatr Drugs. 2012; 14(1):7–12. doi: 10.2165/11595980-000000000-00000.

3. Bzarova ТМ, Alexeeva EI, Lomakina ОL, et al. Use of etanercept in patients with oligoarticular juvenile idiopathic arthritis. Current pediatrics. 2014;13(6): 72–77. (In Russ). doi: 10.15690/vsp.v13i6.1206.

4. Magni-Manzoni S, Pistorio A, Labo E, et al. A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67(8):1159–1164. doi: 10.1136/ard.2007.078121.

5. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41(12):1428–1435. doi: 10.1093/rheumatology/41.12.1428.

6. Tollisen A, Selvaag AM, Aulie HA, et al. Physical functioning, pain and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year follow-up study. Arthritis Care Res (Hoboken). 2018;70(5):741–749. doi: 10.1002/acr.23327.

7. Bullinger M, Hasford J. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials. 1991;12(4 Suppl): 91S–105S. doi: 10.1016/S0197-2456(05)80015-7.

8. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–1409. doi: 10.1016/02779536(95)00112-k.

9. Saxena S, Orley J; WHOQOL Group. Quality of life assessment: the World Health Organization perspective. Eur Psychiatry. 1997; 12 Suppl 3:263s–266s. doi: 10.1016/S0924-9338(97)89095-5.

10. Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48(3):767–775. doi: 10.1002/art.10863.

11. Haverman L, Grootenhuis MA, van den Berg JM, et al. Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a web-based survey. Arthritis Care Res (Hoboken). 2012;64(5):694–703. doi: 10.1002/acr.21609.

12. Manczak M, Rutkowska-Sak L, Raciborski F. Health-related quality of life in children with juvenile idiopathic arthritis—child’s and parent’s point of view. Reumatologia. 2016;54(5):243–250. doi: 10.5114/reum.2016.63665.

13. Bertilsson L, Andersson-Gare B, Fasth A, et al. Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. J Rheumatol. 2013;40(5):715–724. doi: 10.3899/jrheum.120602.

14. Oliveira S, Ravelli A, Pistorio A, et al. Proxy-reported healthrelated quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007;57(1): 35–43. doi: 10.1002/art.22473.

15. Barth S, Haas JP, Schlichtiger J, et al. Long-term healthrelated quality of life in German patients with juvenile idiopathic arthritis in comparison to German general population. PLoS One. 2016;11(4):e0153267. doi: 10.1371/journal.pone.0153267.

16. Gutierrez-Suarez R, Pistorio A, Cespedes Cruz A, et al. Healthrelated quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology (Oxford). 2007;46(2): 314–320. doi: 10.1093/rheumatology/kel218.

17. Solari N, Viola S, Pistorio A, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum. 2008;59(11):1571–1579. doi: 10.1002/art.24202.

18. Oen K, Guzman J, Dufault B, et al. Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis. Arthritis Care Res (Hoboken). 2018;70(1): 134–144. doi: 10.1002/acr.23236.

19. Nordal E, Zak M, Aalto K, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(9):2809–2818. doi: 10.1002/art.30426.

20. Klotsche J, Minden K, Thon A, et al. Improvement in healthrelated quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthritis Care Res (Hoboken). 2014;66(2):253–262. doi: 10.1002/acr.22112.

21. Shaw KL, Southwood TR, Duffy CM, McDonagh JE. Healthrelated quality of life in adolescents with juvenile idiopathic arthritis. Arthritis Rheum. 2006;55(2):199–207. doi: 10.1002/art.21852.

22. van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis. 2015;74(11):1996–2005. doi: 10.1136/annrheumdis-2014-205265.

23. Seid M, Huang B, Niehaus S, et al. Determinants of healthrelated quality of life in children newly diagnosed with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(2):263–269. doi: 10.1002/acr.22117.

24. Seid M, Opipari L, Huang B, et al. Disease control and healthrelated quality of life in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(3):393–399. doi: 10.1002/art.24477.

25. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8.

26. Denisova RV, Al’bitsky VYu, Alexeeva EI, et al. Psychometrical characteristics of Russian versions of PEDSQL Rheumatology Module and PEDSQL Generic Core Scale questionnaires for the estimation of quality of life of children aged from 2 to 4 years old with juvenile rheumatoid arthritis. Current pediatrics. 2008;7(5):39–45. (In Russ).

27. Denisova RV, Alexeeva EI, Al’bitsky VYu, et al. Reliability, validity and sensitivity of Russian versions of PEDSQL Generic Core Scale and PEDSQL Rheumatology Module questionnaires. Current pediatrics. 2009;8(1):30–40. (In Russ).

28. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl. 1999;57:16–21.

29. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and singleattribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–128. doi: 10.1097/00005650200202000-00006.

30. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics. 1995; 7(6):503–520. doi: 10.2165/00019053-199507060-00005.

31. Vinyarskaya IV, Chernikov VV, Terletskaya RN, et al. Validation of the Russian version of a questionnaire for the assessment of utilitarian indices in pediatric practice. Stage II. Current pediatrics. 2014;13(4):20–25. (In Russ). doi: 10.15690/vsp.v13i4.1080.

32. Hunt SM, Alonso J, Bucquet D, et al. Cross-cultural adaptation of health measures. European Group for Health Management and Quality of Life Assessment. Health Policy. 1991;19(1):33–44. doi: 10.1016/0168-8510(91)90072-6.

33. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–525. doi: 10.1136/ard.2007.087593.

34. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–1504. doi: 10.1002/art.23427.

35. Alexeeva ЕI, Bzarova TM, Tsurikova NA, Denisova RV. Results of an open, monocentered non-randomised, without control group, observational quality of life evaluation study in patients with idiopathic juvenile arthritis treated with etarnecept in combination with methotrexate. Current pediatrics. 2011;10(6):26–34. (In Russ).

36. Prince FH, Geerdink LM, Borsboom GJ, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69(1):138–142. doi: 10.1136/ard.2009.111260.

37. van der Meer A, Wulffraat NM, Prakken BJ, et al. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007;25(3):480–485.